🆙#ESMO26 #LCSM Presidential I Discussion🌟
🔥Redefining Possibilities in SCLC. And Maintaining Hope.
🎙️ @StephenVLiu
🎯Attrition and the Rationale for Maintenance Strategies
🎯Biomarkers for Tarlatamab?
🎯Still Challenging SCLC and Access Issues with Tarlatamab
🎯New Hope Under Development in Multiple Trials
🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/346
@OncoAlert @Larvol @myESMO
53 views · 2 likes · 2 reposts · 1 reply
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org🆙#ESMO26 Presidential Symposium I: #LCSM 🔥DeLLphi-305: Tarlatamab Plus Durvalumab (Durva) vs Durva as 1L Maintenance (1LM) Therapy Following Durva, Platinum, and Etoposide in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Primary Analysis of the Phase 3 Trial 🎙️ @sands_jacob 🔢LBA3 🎯Met Primary Endpoint: Significantly Improved OS 🎯mOS 21.1 vs 12.7m, HR 0.42 🎯mPFS 7.4 vs 1.9m, HR 0.34 🎯ORR 26.4% vs 4.1% 🎯CRS 49.6% (Mostly Low Grade), No Fatal Events ☑️NCT06211036 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/346 @OncoAlert @Larvol @myESMO @IASLC在 X 查看被引用的帖子
- CrozrX@CrozrX
How fitting to see attrition take the Presidential Symposium stage at #ESMO26! 🎯 Dr. Liu highlights a striking reality in ES-SCLC: only 37% of patients in the LALUCA registry received second-line therapy. A compelling rationale for maintenance strategies, with the critical balance between disease control, added toxicity and ultimately, survival. This is precisely why I brought real-world attrition into my post of chemotherapy-free strategies in metastatic CRC and PDAC. It matters enormously. Therapeutic trifecta convergence: activity, tolerability, combinability! Different cancers, different therapeutic approaches, but a shared question: How to preserve patients' opportunity to benefit not only from today's treatment, but also from what comes next? @ArndtVogel @RManochakian
Source: Hidehito HORINOUCHI · x.com